Park Place Capital Corp Has $558,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Park Place Capital Corp lifted its position in Johnson & Johnson (NYSE:JNJ) by 63.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 3,526 shares of the company’s stock after acquiring an additional 1,369 shares during the quarter. Park Place Capital Corp’s holdings in Johnson & Johnson were worth $558,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Kennedy Capital Management LLC increased its holdings in Johnson & Johnson by 18.6% during the third quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock worth $3,189,000 after buying an additional 3,206 shares during the last quarter. Shakespeare Wealth Management Inc. increased its holdings in Johnson & Johnson by 4.9% during the third quarter. Shakespeare Wealth Management Inc. now owns 3,467 shares of the company’s stock worth $540,000 after buying an additional 163 shares during the last quarter. Sei Investments Co. increased its holdings in Johnson & Johnson by 0.6% during the third quarter. Sei Investments Co. now owns 975,372 shares of the company’s stock worth $151,914,000 after buying an additional 6,097 shares during the last quarter. Rainsberger Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 2.6% in the third quarter. Rainsberger Wealth Advisors Inc. now owns 14,584 shares of the company’s stock worth $2,271,000 after purchasing an additional 373 shares in the last quarter. Finally, Industrial Alliance Investment Management Inc. increased its stake in shares of Johnson & Johnson by 125.4% in the third quarter. Industrial Alliance Investment Management Inc. now owns 6,671 shares of the company’s stock worth $1,039,000 after purchasing an additional 3,711 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Monday, June 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective for the company. Finally, Morgan Stanley cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $146.03 on Wednesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a market cap of $351.45 billion, a PE ratio of 9.10, a PEG ratio of 2.43 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The company has a 50 day simple moving average of $148.09 and a two-hundred day simple moving average of $153.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $2.68 earnings per share. Analysts expect that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.40%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.